PDF(Pubmed)
Abstract：
The aim of the study was to assess long-term ciclosporin oral solution compliance in cats treated for feline atopic skin syndrome (FASS).
A survey was sent by email to 114 owners who had administered ciclosporin oral solution to their cats for FASS.
In total, 42 owners completed the survey. The population was composed of 30 domestic shorthair cats and 12 pure breeds. There were 20 males and 22 females, and the median age was 5.5 years. Ciclosporin oral solution was administered directly into the mouth in 32/42 (76%) and with food/other in 10/42 (24%) cats. The administration was considered easy in 18/42 (43%) cats, difficult in 23/42 (55%) and impossible in 1/42 (2%). Treatment was stopped in 25/42 (60%) cats. The causes were as follows: administration difficulty (nine cats, 21%); complete resolution (four cats, 10%); treatment failure (four cats, 10%); price (two cats, 4%); and other causes (two deaths, two neoplasia, one adverse effect and one lack of compliance). Adverse effects involving clinical signs were reported in 25 (60%) cats: ptyalism (8/42); dysorexia/anorexia (6/42); vomiting (4/42); diarrhoea (4/42); gingival hyperplasia (1/42); and a combination of vomiting, diarrhoea and ptyalism (2/42). In addition, altered behaviour was reported in 27/42 (64%) cats: hiding in seven cats; scared of owner in 10 cats; modification of sleeping or playing activity in six cats; inappropriate urination/defecation in two cats; aggression in one cat; and all of the above in one cat.
In total, 24 (57%) cats had adverse effects involving both clinical signs and altered behaviour, and only six cats had either adverse clinical signs or behavioural changes. This survey showed that behavioural changes appear to be underestimated in the cats treated with ciclosporin oral solution and this could cause treatment failure due to lack of compliance. Larger-scale studies are needed to confirm these preliminary results.
A survey was sent by email to 114 owners who had administered ciclosporin oral solution to their cats for FASS.
In total, 42 owners completed the survey. The population was composed of 30 domestic shorthair cats and 12 pure breeds. There were 20 males and 22 females, and the median age was 5.5 years. Ciclosporin oral solution was administered directly into the mouth in 32/42 (76%) and with food/other in 10/42 (24%) cats. The administration was considered easy in 18/42 (43%) cats, difficult in 23/42 (55%) and impossible in 1/42 (2%). Treatment was stopped in 25/42 (60%) cats. The causes were as follows: administration difficulty (nine cats, 21%); complete resolution (four cats, 10%); treatment failure (four cats, 10%); price (two cats, 4%); and other causes (two deaths, two neoplasia, one adverse effect and one lack of compliance). Adverse effects involving clinical signs were reported in 25 (60%) cats: ptyalism (8/42); dysorexia/anorexia (6/42); vomiting (4/42); diarrhoea (4/42); gingival hyperplasia (1/42); and a combination of vomiting, diarrhoea and ptyalism (2/42). In addition, altered behaviour was reported in 27/42 (64%) cats: hiding in seven cats; scared of owner in 10 cats; modification of sleeping or playing activity in six cats; inappropriate urination/defecation in two cats; aggression in one cat; and all of the above in one cat.
In total, 24 (57%) cats had adverse effects involving both clinical signs and altered behaviour, and only six cats had either adverse clinical signs or behavioural changes. This survey showed that behavioural changes appear to be underestimated in the cats treated with ciclosporin oral solution and this could cause treatment failure due to lack of compliance. Larger-scale studies are needed to confirm these preliminary results.
摘要：
目的：本研究的目的是评估猫治疗猫科动物特应性皮肤综合征（FASS）的长期环孢素口服溶液的依从性。
方法：通过电子邮件向114名给猫服用环孢素口服液的猫主人发送了一项调查。
结果：总计，42名业主完成了调查。种群由30只家养的短毛猫和12只纯种组成。有20名男性和22名女性，中位年龄为5.5岁.在32/42（76％）的猫中，将环孢素口服溶液直接施用到口中，并在10/42（24％）的猫中与食物/其他一起施用。18/42（43％）猫的给药被认为很容易，23/42(55%)困难，1/42(2%)不可能。在25/42(60%)猫中停止治疗。原因如下：管理困难(9只猫，21%)；完全分辨率(四只猫，10%)；治疗失败(四只猫，10%)；价格(两只猫，4%)；和其他原因(2例死亡，两个肿瘤,一个不利影响和一个缺乏合规性)。据报道，25只(60%)猫出现了涉及临床体征的不良反应：呕吐(8/42)；呼吸困难/厌食(6/42)；呕吐(4/42)；腹泻(4/42)；牙龈增生(1/42)；以及呕吐的组合，腹泻和ptyalism（2/42）。此外,据报道，27/42（64％）猫的行为发生了变化：躲藏在七只猫中；害怕10只猫的主人；六只猫的睡眠或玩耍活动的改变；两只猫的排尿/排便不当；一只猫的侵略；以及所有这些都在一只猫中。
结论：总的来说，24只（57％）猫有涉及临床体征和行为改变的不良反应，只有六只猫有不良的临床症状或行为改变。这项调查表明，在用环孢素口服溶液治疗的猫中，行为变化似乎被低估了，这可能由于缺乏依从性而导致治疗失败。需要更大规模的研究来证实这些初步结果。
方法：通过电子邮件向114名给猫服用环孢素口服液的猫主人发送了一项调查。
结果：总计，42名业主完成了调查。种群由30只家养的短毛猫和12只纯种组成。有20名男性和22名女性，中位年龄为5.5岁.在32/42（76％）的猫中，将环孢素口服溶液直接施用到口中，并在10/42（24％）的猫中与食物/其他一起施用。18/42（43％）猫的给药被认为很容易，23/42(55%)困难，1/42(2%)不可能。在25/42(60%)猫中停止治疗。原因如下：管理困难(9只猫，21%)；完全分辨率(四只猫，10%)；治疗失败(四只猫，10%)；价格(两只猫，4%)；和其他原因(2例死亡，两个肿瘤,一个不利影响和一个缺乏合规性)。据报道，25只(60%)猫出现了涉及临床体征的不良反应：呕吐(8/42)；呼吸困难/厌食(6/42)；呕吐(4/42)；腹泻(4/42)；牙龈增生(1/42)；以及呕吐的组合，腹泻和ptyalism（2/42）。此外,据报道，27/42（64％）猫的行为发生了变化：躲藏在七只猫中；害怕10只猫的主人；六只猫的睡眠或玩耍活动的改变；两只猫的排尿/排便不当；一只猫的侵略；以及所有这些都在一只猫中。
结论：总的来说，24只（57％）猫有涉及临床体征和行为改变的不良反应，只有六只猫有不良的临床症状或行为改变。这项调查表明，在用环孢素口服溶液治疗的猫中，行为变化似乎被低估了，这可能由于缺乏依从性而导致治疗失败。需要更大规模的研究来证实这些初步结果。
